Redx Presents Preclinical Data on RXC008, a Potential First-in-Class Therapy to Treat Fibrostenotic Crohn’s Disease, at the UEG Week
Trinity Delta Report: Redx Pharma
Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination
EQS-News: JP Jenkins Ltd Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Supporting Genetic Selection Hypothesis in Hard-to-Treat GI Cancers 28-Jun-2024 / 10:39 GMT/BSTThe issuer is solely responsible for the content of this announcement. 28th June 2024ISIN: GB00BSNB6S51JPJ:REDX REDX PHARMA LIMITED (“Redx” or the “Company”) Redx Reports Encouraging Zamaporvint (RXC004) […]